Form 4: Rhythm Pharmaceuticals: Executive Stock Transactions

Yann Mazabraud, EVP of International at Rhythm Pharmaceuticals, reports transactions involving common stock and restricted stock units.

Summary

• Yann Mazabraud, Executive Vice President and Head of International at Rhythm Pharmaceuticals, Inc., has reported transactions related to his beneficial ownership of the company's common stock.
• On April 1, 2026, Mazabraud acquired 12,875 shares of common stock.
• Following this acquisition, Mazabraud beneficially owns 66,030 shares of common stock.
• The filing also details transactions involving Restricted Stock Units (RSUs).
• 10,375 RSUs were acquired, representing a contingent right to receive one share of common stock each.
• These RSUs vest in tranches on April 14, 2024, April 14, 2025, April 1, 2026, and April 1, 2027.
• An additional 2,500 RSUs were acquired, which vest in tranches on April 15, 2025, April 1, 2026, April 1, 2027, and April 1, 2028.
• The total number of RSUs beneficially owned after these transactions is 15,375 (10,375 + 5,000 from prior grants, assuming the 2,500 are new grants and the 5,000 is the remaining balance of a prior grant).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it primarily reports routine executive stock transactions and compensation rather than company performance or strategic shifts.

Positives

• Executive leadership is actively involved in the company's stock, indicated by the acquisition of common stock.
• The vesting schedules for RSUs suggest a long-term incentive structure designed to retain key personnel.
• The acquisition of 12,875 shares of common stock on April 1, 2026, indicates a direct investment by the executive.

Negatives

• The filing does not provide financial performance data, making it difficult to assess the company's overall health.
• The nature of the transactions (acquisition of stock and RSUs) is typical for executive compensation and does not inherently signal positive or negative company performance.

Risks

• The vesting schedules for RSUs are tied to specific future dates, meaning that if the executive departs before vesting, these units may be forfeited.
• The value of the RSUs is directly tied to the company's stock performance, exposing the executive to market risk.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's financial performance or strategic direction. It solely reports on executive stock transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The acquisition of stock and RSUs by an executive like Yann Mazabraud is typical for compensation and incentive alignment within the biopharmaceutical industry, where long-term commitment is valued.

Stakeholder Impact

• Shareholders: The transactions indicate continued executive commitment and investment in the company, which can be viewed positively. However, the filing provides no information on company performance that would directly impact share value.
• Employees: The RSU vesting schedules reinforce the company's strategy of using equity to retain key talent.
• Management: The transactions reflect the standard compensation and incentive structure for senior executives.

Next Steps

• Continued vesting of Restricted Stock Units according to the outlined schedules.
• Potential future transactions by the reporting person, which will be disclosed via subsequent Form 4 filings if they meet reporting thresholds.

Key Dates

Keywords

Form 4, SEC Filing, Rhythm Pharmaceuticals, RYTM, Stock Transaction, Beneficial Ownership, Restricted Stock Units, Executive Compensation, Insider Trading, Securities Exchange Act